Mitochondrial M2 Antibody Test

Mitochondria M2 antibodies (AMA-M2) are a special kind of immune protein that mistakenly targets key enzymes inside the mitochondria, the structures in our cells that create energy. Specifically, AMA-M2 attacks the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), a major enzyme involved in helping cells convert food into energy.

In a healthy immune system, antibodies defend against infections. However, when the body produces AMA-M2, it suggests a breakdown in normal immune regulation. This antibody is strongly associated with primary biliary cholangitis (PBC), a chronic autoimmune disease where the body’s immune system gradually destroys the small bile ducts in the liver. Bile ducts help remove waste from the liver and aid in digestion. Damage to these ducts can lead to liver inflammation, scarring (fibrosis), and eventually liver failure if untreated.

AMA-M2 is found in about 95% of people with PBC, making it an excellent marker for diagnosing the disease. Studies show a sensitivity (ability to detect true cases) around 84.5% and specificity (ability to avoid false positives) around 97.8%.

AMA-M2 mostly shows up as the IgG type of antibody, which is the most common antibody in our blood and is involved in long-term immune defense. Some tests can also detect the IgA type, often found in mucous membranes like the gut and lungs. While higher levels of IgG AMA-M2 may suggest a more active or severe disease, the presence of these antibodies, regardless of type, does not necessarily predict how fast PBC will progress.

AMA-M2 can occasionally appear at low levels in other conditions, like chronic liver disease or even recurrent urinary tract infections. However, when found at significant levels and with the right clinical symptoms, it remains highly specific to PBC. Other autoimmune diseases like systemic lupus erythematosus (SLE) can involve mitochondria-targeting antibodies, but only rarely do they include AMA-M2, and when they do, the target is usually different.

Researchers believe that AMA-M2 may develop through molecular mimicry, a situation where bacterial proteins look so similar to human mitochondrial proteins that the immune system gets confused and starts attacking its own tissues. Certain bacteria, such as E. coli, seem to share these similarities, and recurrent infections may increase the risk. Recently, it has even been found that antibodies created in response to SARS-CoV-2 (the virus that causes COVID-19) might also cross-react with mitochondrial proteins like M2, raising questions about new autoimmune risks following viral infections.